OHDSI Home | Forums | Wiki | Github

Researchers


About the Researchers category (1)
Feasibility of Network studies that use the NOTE, NOTE_NLP, and Flowsheets (3)
Study launch: Evaluating the Iodine-131 exposure effect on the occurrence of secondary cancer in survivors of thyroid cancer (2)
How to find the ancestor_concept_id of the condition_concept_id in the condition_occurrence table? (13)
Has the homepage address changed? (http://omop.org/HOI) (3)
CDC Collaboration (3)
Cohort pathway : why in the same first circle,the same drug sometimes tend to be in central, sometimes tend to be for second circel? (2)
Adding a new cohort from Synthea generated csv files to an existing CDM (3)
The meaning of 'minDaysAtRisk' argument (3)
Standardizing procedures (call for non-US based collaborators) (18)
Dexamethasone Cohort Building (4)
Cohort pathway: the unreasonable proporation (3)
Hematology projects? (3)
CohortMethod user group ( 2 3 4 ) (73)
Cohort pathway: why Persons with pathways portion are not equal to 100%? (5)
Empty cohort issue only occurred on KNN, Naive Bayes, Neural Network, DeepNN model (5)
Atlas: How to set index date to absolute day or to get_todays_date() (4)
Negative information in OMOP CDM (11)
Atlas Cohort Definition (Eligibility requirement of more than 1 occurrence of a diagnosis) (4)
Research Collaboration: NANOTIZED HERBAL MEDICINE FOR BURNS- FROM CONCEPT TO APPLICATION (1)
Feature Analysis/Cohort Characterization Tool in ATLAS (3)
COVID-19 study-a-thon data (1)
COVID-19 infections in cancer patients (12)
[COVID-19] Prior immunization as protective for COVID-19 disease/bad outcomes (3)
ICU data, anyone? (19)
[OHDSI Covid19] Literature review on viral prediction models ( 2 ) (23)
Characterization of Oral Antibiotic and Isotretinoin Therapy for Acne (4)
Forming external controls for comparative effectiveness estimation (3)
Do your Rx dispensation data have refills? (USA vs other countries) (6)
[Covid-19] Alpha-1 blocker as potential prophylaxis against ARDS ( 2 ) (22)
t